Dr. Michael Har-Noy Develops Unique Cancer Drugs

18 Sep

Physicians have been largely unsuccessful in treating patients with metastatic cancer. Medical scientists have made significant advances in early cancer diagnosis and prevention in the past two decades, but they have made relatively few inroads in treating advanced malignant disease.

The principle problem with current cancer therapies is that they usually cannot eradicate every cancer cell. Furthermore, as in the case of chemotherapy and radiation, they are often very toxic to the body and have unacceptable side effects. A young, daring biotech company named Immunovative Therapies Ltd., founded by Dr. Michael Har-Noy, is hoping to vastly improve the way cancer is treated. Dr. Michael Har-Noy is now testing groundbreaking drugs that enable one’s own immune system to kill metastatic cells.

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, describes their flagship product, AlloStimTM, as a biological drug synthesized from precursors found in the circulation of a normal donor. These precursors are then purified, differentiated, expanded, and then frozen until needed. When infused into a cancer patient’s blood these unique cells create an inflammatory environment which disarms tumor avoidance mechanisms. Because AlloStimTM cells are intentionally mismatched and are seen by the host as foreign, the patient’s own immune system “wakes up” to these danger signals and is able to both reject the AlloStimTM cells and kill the tumor cells.

Dr. Michael Har-Noy, using this patented “Mirror EffectTM” described above, has essentially produced the tumor-killing effect of a successful allogeneic bone marrow transplant without exposing the patient to the lethal problem of graft versus host disease.

Preliminary Phase I/II data shows that AlloStimTM has a remarkable antitumor effect across a wide variety of metastatic cancers. A Phase II/III trial of AlloStimTM in the treatment of metastatic breast cancer will hopefully be under way soon in Thailand. With his unique biologic drugs, Dr. Michael Har-Noy may be on the verge of creating an entire new field of oncology.

%d bloggers like this: